Addressing Residual Reagents and Impurities in Drug Development, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how residual reagents and impurities can be identified, assessed and controlled throughout drug development. The featured speakers will discuss risk-based analytical strategies, fit-for-purpose assays and specification setting for small molecules, biologics and advanced therapies. Attendees will also explore how impurity control strategies can evolve as process and product knowledge increases across development.

TORONTO, Sept. 21, 2026 /PRNewswire/ -- In this free webinar, learn how residual reagents and impurities can be identified, assessed and controlled throughout drug development. The featured speakers will discuss risk-based analytical strategies, fit-for-purpose assays and specification setting for small molecules, biologics and advanced therapies. Attendees will also explore how impurity control strategies can evolve as process and product knowledge increases across development.

BODY:

Residual reagents and process- or product-related impurities can affect product safety, efficacy and regulatory acceptance across small-molecule, biologic and advanced-therapy programs. Their control requires a risk-based strategy that links process understanding, analytical method development and appropriate specification setting throughout development.

This webinar explores practical approaches for identifying critical residuals or impurities, assessing their potential impact and developing fit-for-purpose assays to support process optimization, release testing and characterization. The session will consider how analytical strategies can be tailored to the nature and risk of individual impurities, helping development teams generate appropriate data to inform quality and safety decisions.

Attendees will learn how sensitive and selective analytical platforms can be integrated with lifecycle-based control strategies to support robust, compliant and scalable drug development. It will also examine how testing requirements, specifications and control approaches may change as greater process and product knowledge is established, helping maintain an appropriate strategy as programs progress toward later-stage development.

Register for this webinar to learn how impurities can be identified, assessed and controlled through risk-based analytical strategies across drug development.

Join Alaknanda Mishra, PhD, Director of Advanced Therapeutics, BA Sciences; and Ramakrishna Battula, MSc, Senior Scientist, BA Sciences, for the live webinar on Tuesday, October 13, 2026, at 1pm EDT.

For more information, or to register for this event, visit Addressing Residual Reagents and Impurities in Drug Development.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:

Soumya Shashikumar

Tel: +1 (416) 977-6555 x371

Email: [email protected]

SOURCE Xtalks